Background: Two randomized trials recently demonstrated that regional nodal irradiation (RNI) could reduce the risk of recurrence in early breast cancer; however, these trials were conducted in the pretrastuzumab era. Whether these results are applicable to human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients treated with anti-HER2-targeted therapy is unknown. Methods: This retrospective analysis was performed on patients with node-positive breast cancer who were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization phase III adjuvant trial and subjected to BCS. The primary objective of the present study was to examine the effect of RNI on disease-free survival (DFS). A multivariable cox regression analysis adjusted for number of positive lymph nodes, tumor size, grade, age, hormone receptors status, presence of macrometastatis, treatment arm, and chemotherapy timing was carried out to investigate the relationship between RNI and DFS. Results: One thousand six hundred sixty-four HER2-positive breast cancer patients were included, of whom 878 (52.8%) had received RNI to the axillary, supraclavicular, and/or internal mammary lymph nodes. Patients in the RNI group had higher nodal burden and more frequently had tumors larger than 2 cm. At a median follow-up of 4.5 years, DFS was 84.3% in the RNI group and 88.3% in the non-RNI group. No differences in regional recurrence (0.9 % vs 0.6 %) or in overall survival (93.6% vs 95.3%) were observed between the two groups. After adjustment in multivariable analysis, there was no statistically significant association between RNI and DFS (hazard ratio ¼ 0.96, 95% confidence interval ¼ 0.71 to 1.29). Conclusions: Our analysis did not demonstrate a DFS benefit of RNI in HER2-positive, node-positive patients treated with adjuvant HER2-targeted therapy. The benefit of RNI in HER2-positive breast cancer needs further testing within randomized clinical trials.
Adjuvant radiation therapy has an important role in the multidisciplinary management of early breast cancer. Whole-breast irradiation (WBI) after breast-conserving surgery (BCS) reduces the rate of breast cancer recurrence and breast cancer-related death and is considered standard of care for these patients (1) . However, the role of regional nodal irradiation (RNI) has been a persistent source of debate as studies have been inconsistent in demonstrating benefit from RNI to prevent loco-regional recurrence (2) (3) (4) . Moreover, recent studies suggest that neither axillary lymph node dissection (ALND) nor RNI may be necessary for small clinically node-negative breast tumors with one to three positive lymph nodes detected by sentinel lymph node biopsy (SLNB), provided that WBI is administered after BCS (5, 6) . On the other hand, two recently published randomized trials, the MA.20 and the EORTC 22922 trials, have demonstrated a benefit from RNI on the rate of locoregional recurrence and distant metastases (7, 8) . Both trials included either patients with node-positive disease or nodenegative patients considered at high risk of relapse, irrespective of hormone receptor or human epidermal growth factor receptor 2 (HER2) status. Although the two trials did not show an overall survival (OS) benefit, they are the first to robustly demonstrate that aggressive regional treatment improves disease-free survival (DFS) in node-positive or high-risk early breast cancer patients.
During the last 15 years, the understanding of the biology of breast cancer has greatly evolved (9,10) The introduction of anti-HER2-targeted therapies has revolutionized the treatment of HER2-positive breast cancer, with important gains obtained in OS and DFS (11) . An unanswered question is whether adjuvant RNI is associated with the same benefit demonstrated in the MA. 20 and EORTC 22922 trials in the context of modern adjuvant treatment including anti-HER2-targeted therapies, which were not administered in these trials.
Recently, the results of the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial, the largest adjuvant trial to date in the field of HER2-positive breast cancer, were reported (12) . The main analysis indicated a statistically nonsignificant 16% reduction in the DFS hazard rate in patients treated with trastuzumab and lapatinib combination compared with those treated with trastuzumab, both given for one year. In the current analysis, we evaluated the impact of RNI on DFS in HER2-positive node-positive breast cancer patients enrolled in ALTTO.
Methods

Study Design and Patients
The ALTTO trial is an international open-label randomized phase III adjuvant trial in which centrally confirmed HER2-positive breast cancer patients were randomly assigned to one of four arms: adjuvant intravenous (IV) trastuzumab (T) alone, oral lapatinib (L) alone, sequential IV trastuzumab followed by oral lapatinib (T!L), or concomitant IV trastuzumab and oral lapatinib (LþT), all for a total duration of one year (NCT00490139). The trial was conducted between June 2007 and July 2011 and enrolled 8381 patients from 44 countries. Investigators could administer anti-HER2 therapy either at the end of completion of all chemotherapy, or combined with a taxane. Further details regarding eligibility criteria and study design are provided in the original publication (12) . All patients gave written informed consent, and institutional review board/institutional ethics committee approval to conduct the study was mandatory for all participating centers.
The primary end point of the ALTTO trial was DFS, defined as the time from random assignment to recurrence of invasive breast cancer, contralateral invasive breast cancer, second nonbreast malignancy, or death from any cause, whichever occurred first. Secondary end points included OS, safety, cardiac safety, time to recurrence, time to distant recurrence, and time to first brain metastasis. As per inclusion criteria, either upfront ALND or SLNB was to be performed for all patients, and completion of ALND was mandatory for all patients with a positive SLNB.
Per protocol, all patients subjected to BCS had to receive WBI. RNI was administered at the discretion of the local investigator according to institutional guidelines and was not mandated by the ALTTO protocol. However, discretionary recommendations for RNI treatment were included in the protocol: RNI was suggested for patients with zero to three positive nodes, and strongly recommended for patients with four or more positive nodes; RNI to the internal mammary nodes (IMN) was recommended in case of suspicion of IMN involvement by sentinel nodes procedure; three-dimensional conformal radiotherapy was recommended in case of IMN irradiation to minimize cardiac irradiation. There were no recommendations for doses, fields, or radiotherapy technique. Areas treated were reported on the case report as follows: breast, chest wall, axillary nodes, supraclavicular nodes, IMN, and other, with the actual doses and dates of treatment. Boost administration was reported separately.
Definitions and Objectives
For the main analysis, only patients with node-positive disease having been treated with BCS were included. Patients who received neoadjuvant chemotherapy were excluded from the analysis because of the nonreliability of the pathological lymph node evaluation. RNI was defined as irradiation to the axillary nodes, supraclavicular nodes, and/or IMN site. Patients having received treatment to either one or more of these regions were considered to have received RNI.
The primary objective was to examine the effect of RNI on DFS in patients with lymph node-positive breast cancer treated with BCS in the ALTTO trial. Secondary objectives were to evaluate the effect of RNI on OS, local and regional recurrences, and distant disease-free survival (DDFS), and to examine the patterns of RNI administration in this population. In a second step, the effect of RNI on DFS was explored in patients with nodepositive disease treated with mastectomy.
Statistical Analysis
Patient characteristics were summarized for patients treated with BCS who had received or did not receive RNI. The clinical decision to administer RNI is influenced by lymph node status, and so this should feature in any formal statistical analysis; therefore, P values were not calculated for Table 1 . For this reason, an additional table considered those with one to three positive lymph nodes and four or more positive lymph nodes as two groups; for this table, differences in number of lymph nodes between the RNI and non-RNI groups were tested using the Wilcoxon two-sample test, and all other patient characteristics were tested using chi-squared tests.
Summaries of type of regional areas treated, number of regions treated, and dose administered were calculated, as well as a summary of RNI administration by geographical area. Cox proportional hazards models, which included patients' characteristics in univariate models, were fitted to DFS in two separate analyses, one for the BCS group and one for the mastectomy group. The assumption of proportionality was assessed by fitting timevarying covariates, which were interactions between the covariate of interest and time to DFS. All covariates were included in a multivariable model adjusted for age, tumor size, grade, hormone receptor status, presence of macrometastatis, treatment arm, number of positive lymph nodes, chemotherapy timing, chest wall irradiation (CWI; only for the mastectomy group) and RNI.
All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant.
Results
Patient Characteristics
A total of 1664 patients (19.8%) met the inclusion criteria for the main analysis (Table 1 ). Approximately half of the patients (878/ 1664, 52.8%) received RNI. Age, histologic grade, hormone receptor status, and treatment allocation were well balanced between the non-RNI and RNI groups. However, the number of patients with four or more positive lymph nodes was considerably higher in the RNI group (55.2% vs 13.4%). Likewise, numerically more patients in the RNI group had macrometastasis (53.0% vs 43.8%) and tumors larger than 2 cm (52.8% vs 44.1%). Because of the substantial imbalance in nodal burden between patients having received RNI or not, we also compared the patients' characteristics after stratification for nodal burden (one to three positive lymph nodes vs four or more positive lymph nodes) (Supplementary Table 1 , available online).
Patterns of RNI Administration
Only a third of the patients with one to three positive lymph nodes (393/1068, 36.8%) received RNI, while 82.2% of patients with four or more positive lymph nodes were treated with RNI. Of patients receiving RNI, 60.9% had treatment that targeted only one regional node area, while only 3.9% received RNI targeting the three regional nodal areas. The supraclavicular nodes, axillary nodes, and IMN were treated, respectively, in 86.8%, 41.1%, and 14.9% of patients, with a median cumulative dose of 49-50 Gy for all regional areas ( Table 2) . Differences in RNI administration were observed across geographical areas. Less than 40% of patients received RNI in Oceania (Australia and New-Zealand) and in Southern Europe (Spain, Greece, Italy, and Slovenia), while approximately half or more of the patients received RNI in the other geographical areas ( Table 3) . The proportion of patients receiving RNI to the IMN was lower than for the other nodal regions in all geographical areas, but the proportion of patients treated was the highest in Western Europe (14.7%) and Scandinavia (14.5%). No patient received IMN irradiation in Africa, Oceania, or the United Kingdom/Ireland.
Efficacy
At a median follow-up of 4.5 years, the total number of DFS events was 230 (13.8%). DFS was 84.3% in the RNI group compared with 88.3% in the non-RNI group (Table 4 ). The number of regional recurrences was very low, with less than 1% of regional recurrence observed in both the RNI (0.9%) and the non-RNI (0.6%) groups. There was no difference in local recurrences; however, there was proportionally more distant recurrence in the RNI group (12% vs 5% in the non-RNI group). OS was comparable between the two groups (93.6% for the RNI group vs 95.3% for the non-RNI group). The number of DFS events after stratification for nodal burden is provided in Supplementary 
ARTICLE
In a second step, we explored the effect of RNI on DFS in the 2658 node-positive patients treated with mastectomy in the ALTTO trial. As for the BCS patients, there was numerical imbalance between groups for nodal burden, tumor size, SNLB, and macrometastasis (patient characteristics are available in Supplementary Table 3, available online). There was more CWI performed in the RNI group (95.7% vs 23.4%). The rate of regional recurrence was also very low for these patients (0.9% for the RNI group and 1.3% for the non-RNI groups). There was no statistically significant association between RNI and DFS in multivariable analysis (HR ¼ 0.82, 95% CI ¼ 0.63 to 1.08, P ¼ .15) ( Table 6 ).
Discussion
The local treatment of the regional nodal areas after BCS is an area of controversy. While some studies support avoiding any regional treatment for patients with a low nodal burden because of the low risk of loco-regional recurrence (5), the MA. 20 and EORTC 22922 studies demonstrated that RNI can improve the rate of loco-regional as well as distant recurrences in patients with high-risk or node-positive disease (7, 8) . However, these trials were conducted before standard application of adjuvant trastuzumab. In our study, we sought to explore whether the benefit observed in these trials also applies to HER2-positive breast cancer patients treated with anti-HER2-targeted therapies.
Our analysis did not demonstrate a DFS improvement with RNI in the HER2-positive breast cancer population treated with adjuvant chemotherapy and targeted therapies. DFS was poorer in the RNI group, which is likely explained by the higher-risk profile of the patients selected for RNI (higher nodal burden, larger tumors, and more macrometastasis). Interestingly, the difference observed in DFS was mostly driven by the number of distant recurrences, and not by regional recurrences. However, the number of regional recurrences may be underestimated because there was no routine imaging performed during followup except for annual mammography. After adjusting for confounding factors, there was still no trend for association between RNI administration and improved DFS. Although our main analysis focused on patients treated with BCS who all received WBI, we also explored the effect of RNI in patients treated with mastectomy, some of whom did not receive any form of radiation. No statistically significant benefit from RNI was observed in this population either.
The rationale behind the regional nodal treatment of early breast cancer patients is to eradicate microscopic residual disease to prevent regional recurrence, and eventually the development of distant metastasis. In our cohort, the rate of regional recurrence was very low (1% in both the RNI and non-RNI group). This compares with the regional recurrence rate described in the ACOSOG Z0011 study, a study randomizing clinically T1-T2 N0 M0 breast cancer patients with one to three positive lymph nodes detected by SLNB to either ALND or no further regional treatment. In the latter study, the regional recurrence rate at a median follow-up of 6.3 years was 0.9% in the "no further treatment" arm and 0.5% in the ALND arm (5). In the MA.20 and the EBCTCG 22922 trials, the regional recurrence rates in the control group at 10 years were 2.5% and 4.2%, respectively, despite generally lower nodal infiltration compared with our study (36% with four or more positive lymph nodes in our cohort vs 5% and 12.5% in the MA.20 and EORTC 22922 trials, respectively). Estrogen receptor-negative and HER2-positive status have been identified in the past as risk factors for loco-regional recurrence, and some groups advocated giving RNI preferentially for these patients (13) (14) (15) (16) (17) . However, there has been considerable improvement in the adjuvant treatment for HER2-positive early breast cancer in the last years with the use of more aggressive chemotherapy regimens (with taxanes) and the introduction of adjuvant trastuzumab. In the MA.20 trial, only 25% of patients received taxane-based chemotherapy, and almost none received anti-HER2-targeted therapy. Our study suggests that some HER2-positive node-positive patients may have a very favorable outcome in the era of application of modern systemic adjuvant therapy and that these patients may not benefit from additional regional treatment. Interestingly, the rate of regional recurrence was also very low in mastectomy patients, even though some patients did not receive any form of radiation therapy.
The ALTTO trial was conducted between 2007 and 2011, before the first presentation of the MA.20 and EORTC 22922 results. Before these trials, evidence on the benefit of RNI was scarce for patients with low nodal burden, which may explain why only 37% of the patients with one to three positive lymph nodes received RNI (3, 4, 18) . We observed important variability in the pattern of RNI administration according to different geographical areas, which stress the lack of strong consensus in the field. Very few patients received IMN irradiation because previous trials had shown conflicting results and an increased risk of cardiac toxicities (2, (18) (19) (20) (21) (22) (23) . On the contrary, in the EORTC 22922 and MA.20 trials, all patients randomized into the RNI group received IMN irradiation. A recent cohort study by the Danish Breast Cancer Group suggests that IMN irradiation increases overall survival in early breast cancer (24) . Patients with a high axillary nodes burden are at increased risk of IMN involvement (25) , and it is plausible that IMN irradiation plays an important role in the effect of RNI observed in the aforementioned trials. Low IMN irradiation rate in our cohort may therefore partly explain our negative results. Nevertheless, with the high four-year OS observed in HER2-positive breast cancer patients treated with adjuvant trastuzumab and chemotherapy (94% in ALTTO), it is likely that benefit from additional IMN irradiation in this population would be minimal. The wide variability in RNI administration and low rates of IMN irradiation in our study underscore the need for guidelines in the field such as those recently published for mastectomy patients (26) .
Our study has a few drawbacks that should be pointed out. First, all patients included in our analysis were treated with ALND, so the results may not be applicable to patients approached with SLNB alone. However, it is worth noting that most of the patients included in the MA.20 and EORTC 22922 trials were also treated with ALND. Second, because of the retrospective, nonrandomized nature of our analysis, important selection bias was introduced, with patients in the RNI group presenting a more high-risk profile. To control for that, we adjusted for confounding factors in multivariable analysis; however, it is possible that factors unaccounted for in this analysis, such as lympho-vascular invasion or extracapsular node extension, may still have influenced the results. Third, although the ALTTO data set included detailed information on targeted regional nodal treatment, data on tangential treatment of regional areas were not collected, nor was the radiation therapy technique used, and no quality analysis for radiation therapy was performed during the trial. This may have led to misclassification of some patients. Finally, this analysis was not prospectively powered, as reflected in the wide confidence intervals for the hazard ratios. The follow-up was relatively short, although patients with HER2-positive disease tend to relapse early compared with luminal tumors (27) (28) (29) , and thus it is unlikely that the results would differ considerably with longer follow-up. Nevertheless, our study is the first to explore the effect of RNI in HER2-positive breast cancer patients treated with modern systemic therapy. Observational and randomized studies in radiation therapy are very challenging, given the rapid evolution in techniques and large variability in practices (30) . Prospective data addressing the use of RNI in HER2-positive breast cancer may take years to obtain if a clinical trial addressing this question is ever conducted. On the other hand, RNI is associated with mildly increased toxicities, as was highlighted by the higher rate of acute dermatitis (49% vs 40%, P < .001) (7), acute pneumonitis (1.2% vs 0.2%, P ¼ .01) (7), lymphedema (8.4% vs 4.5%, P < .001) (7), late radiation skin changes (6.9% vs 4.3%, P ¼ .02) (7), and late pulmonary toxicity (4.4% vs 1.7%, P .001) (8) reported in the MA.20 and EORTC 22922 trials (7, 8) . Although the results of our study are hypothesis generating and have to be interpreted with caution, they highlight the need to identify a subset of patients that may truly benefit from RNI. Our analysis also underscores the importance of characterizing breast cancer subtype in radiation therapy trials.
In conclusion, our study suggests that RNI as administered in the ALTTO trial does not have statistically significant impact on DFS in node-positive, HER2-positive early breast cancer patients treated with BCS, ALND, and WBI, especially for patients with low lymph node burden, and that the rate of regional recurrence for this population is very low. In the era of modern systemic therapy of HER2-positive patients, our analysis questions the need to systematically offer RNI to patients with HER2-positive, lymph node-positive disease.
